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Background: Mammographic density represents epithelial and stromal proliferation, while 
Insulin-like growth factor (IGF)-1, IGF-binding protein (IGFBP)-3, growth hormone (GH) 
and estrogen, may influence cellular proliferation. However, whether these growth factors 
independently, or in combination with estrogen, influence mammographic density in 
premenopausal women remains unclear.  
Material and methods: Growth factors were assessed in 202 ovulating premenopausal 
women participating in the Energy Balance and Breast cancer Aspects (EBBA)-I study. 
Estrogen was assessed in serum, and daily in saliva, throughout a menstrual cycle. Computer-
assisted mammographic density (Madena) was obtained from digitized mammograms (days 
7-12 of the menstrual cycle). Associations between growth factors, estrogen and percent 
mammographic density, were studied in regression models.  
Results: Women with a mean age of 30.7 years had a mean percent mammographic density 
of 29.8%. Among women in the strata (above median split) of IGF-1 (>25 nmol/l) or GH 
(>0.80 mlU/l), we observed that an increase in salivary 17β–estradiol, was associated with a 
higher odds for having higher percent mammographic density (>28.5 %). The odds ratios 
(ORs) per standard deviation increase of 17β-estradiol, were 1.81 (95% confidence interval 
[CI] 1.08-3.03) in the high IGF-1 stratum, and 2.08 (95% CI 1.10-3.94) in the high GH 
stratum. Furthermore, women in this strata of growth factors (above median) who had an 
overall average 17β–estradiol above median (>16.8 pmol/l), had higher ORs for having higher 
percent mammographic density (>28.5%): IGF-1 4.13 (95% CI 1.33-12.83), and GH 4.17 
(95% CI 1.41-12.28).  
Conclusion: Growth factors, in combination with cycling estrogen, were associated with 
percent mammographic density, of potential clinical relevance.  
 
 
 
 
 
 
 
 
 
 
Introduction 
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Mammographic density represents epithelial and stromal proliferation, and is a strong 
biomarker for breast cancer development [1]. Ovarian steroid hormones and growth factors, 
on the other hand, increase cellular proliferation in the breast, which may be reflected through 
mammographic density. Furthermore, the growth hormone (GH)–insulin-like growth factor-1 
(IGF-1) signaling pathway, has been associated with breast cancer [2,3], and IGF-1 is 
suggested to influence cellular proliferation and inhibit apoptosis through the activation of 
PI3/Akt pathway, in both normal breast cells and breast cancer cell lines [4,5].  The level of 
IGF-1 is regulated by GH, and modulated by insulin-like growth factor-binding protein-3 
(IGFBP-3). However, whether IGF-1, IGFBP-3 and GH, independently or in combination 
with ovarian steroid hormones, influence mammographic density among premenopausal 
women, remains unclear [6,7].  
Mammographic density may be described by percent and absolute density. While 
percent mammographic density represents the fibroglandular tissue and fat tissue, absolute 
mammographic density represents the dense area. Mammographic density has been reported 
to vary during the menstrual cycle [8,9], and breast cancer risk factors, including the use of 
exogenous hormones, have been studied mostly in relation to, and associated with, percent 
mammographic density [10,11] and breast cancer development [12,13]. Recently, endogenous 
sex hormone levels and percent mammographic density were associated with breast cancer 
risk, both independently and in combination [14]. Interestingly, it has been hypothesized that 
a crosstalk operates between estrogen and the GH-IGF-1 signalling pathways in cells [15-18]. 
Thus, it is interesting to examine whether the variation in the GH-IGF axis in combination 
with circulating concentrations of estrogen is associated with mammographic density, 
described by both percent and absolute density in premenopausal women.  
Previously, in the Norwegian Energy Balance and Breast cancer Aspects (EBBA)-I 
study, we have observed a positive association between daily circulating ovarian sex 
hormones and mammographic density, using a modified Wolfe classification [19]. In 
addition, 17β-estradiol profiles were associated with traditional breast cancer risk factors, 
such as age at menarche [19,20], insulin, adult height and metabolic profile in adulthood 
[21,19,22]. These associations also point to the need for further studies of estrogen in 
combination with the GH-IGF signalling pathway and mammographic density. 
Thus, the purpose of this study is to examine whether IGF-1, IGFBP-3 and GH, in 
combination with circulating concentrations of daily 17β-estradiol, are associated with 
mammographic density in premenopausal women. A unique aspect of the current study is the 
measurement of estrogen in both serum and daily in saliva. The daily salivary 17β-estradiol 
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measured throughout an entire menstrual cycle represents biologically free active estrogen 
[23]. To facilitate comparisons with other studies and factors affecting various types of breast 
density, both percent and absolute density have been included. 
 
Materials and methods: 
Participants and study design 
The Norwegian EBBA–I study was conducted in 2000–2002 in Tromsø. It included 204 
healthy women aged 25-35 years, with regular menstrual cycles (length 22-38 days) [19,22]. 
The women did not use any daily medication, or steroid contraceptives, in the 6 months prior 
to recruitment, they were not pregnant or lactating, and had no gynaecological or chronic 
disorders (e.g. diabetes, hypothyroidism) [19]. Participants’ characteristics, including 
reproductive and lifestyle factors, were collected by a trained nurse using questionnaires and 
interviews at the time of recruitment. Recall and memory-probing aids, including a lifetime 
calendar, were used to date specific life events. Two women were excluded due to missing 
mammographic data, resulting in 202 participants in the present study.  
 
Clinical examination 
All participants underwent clinical examinations at the Clinical Research Centre, University 
Hospital of North Norway, Tromsø. They attended three scheduled visits during their 
menstrual cycle, after onset of the menstrual bleeding (first visit days 1-5, second visit days 7-
12 and third visit days 21-25). Anthropometric measurements were conducted with 
participants wearing light clothing and no footwear. Height was measured to the nearest 0.5 
cm, and weight to the nearest 0.1 kg on a regularly calibrated electronic scale. Body mass 
index (BMI) was calculated as weight in kilograms per height in square meter (kg/m2). Waist 
circumference (WC) was measured to the nearest 0.5 cm, 2.5 cm above the umbilicus. A 
whole body scan was obtained at the second visit for the estimation of the total percentage of 
fat tissue, using dual-energy X-ray absorptiometry (DEXA; DPLX-L 2288, Lunar Radiation 
Corporation, Madison, WI, USA). The percentage of fat tissue was estimated using Lunar 
software. 
 
 
 
 
Collection and analysis of fasting serum samples 
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Fasting serum samples were drawn in the morning from the antecubital vein at the three 
scheduled visits. Serum glucose was measured enzymatically using the hexokinase method at 
the Department of Clinical Chemistry, University Hospital of North Norway, Tromsø.   
 
Collection of hormones – IGF-1, IGFBP-3, GH and estrogen 
Fasting morning blood samples of insulin, IGF-1 and IGFBP-3, were obtained at the first 
scheduled visit, and fasting serum concentrations of GH was obtained at the second scheduled 
visit. Insulin, IGF-1 and IGFBP-3, were measured in serum stored at –70oC for up to 3 years 
until analysis took place at the Hormone Laboratory, University Hospital of Oslo, Aker. 
Serum insulin was measured by radioimmunoassay (RIA) using kits from Linco Research Inc 
(St.Charles, MO, USA). IGF-1 and IGFBP-3, measured as glycosylated, were determined by 
ILMA, Immulite 2000 (Diagnostic Products Co, Los Angeles, CA, USA). GH was measured 
in serum, stored at –70oC for up to 10 years until analysis, which took place at the Hormone 
Laboratory, University Hospital of Oslo, Aker. DELFIA kits from PerkinElmer Life Sciences 
(Wallac Oy, Turku, Finland) were used for the GH analysis. The coefficients of variation 
(CVs) derived from the laboratories were as follows: 7-10% for IGF-1 and 6% for IGFBP-3. 
For GH the average intra-assay variability was 1.9%, and the inter-assay variability ranged 
from 5.5% for low pools (0.29 mlU/l) to 2.5% for high pools (38.7 mlU/l). 
 Fasting serum 17β-estradiol concentrations were measured consecutively, by direct 
immunometric assay (Immuno-1, Bayer Diagnostics, Norway), at the three scheduled visits 
during the menstrual cycle.  
The participants self-collected daily morning saliva samples, into plastic tubes 
pretreated with sodium azide, starting on the first day of bleeding, for one menstrual cycle, 
according to collection protocols previously established at the Reproductive Ecology 
Laboratory, Harvard University, USA [19,24,25]. Levels of salivary 17β-estradiol 
concentrations, were measured in daily saliva samples from 20 days (reverse cycle days −5 to 
−24; with the last day of the menstrual cycle designated -1) using 125I-labelled RIA kits 
(#39100, Diagnostic Systems Laboratories, Webster, TX, USA), along with published 
modifications of the manufacturer’s protocols [19]. Overall average 17β-estradiol 
concentrations, was calculated using daily levels of 17β salivary- estradiol. All samples were 
run in duplicate, and from a single participant, all samples were run together in the same assay 
with women randomly assigned to assay batches. The CVs were calculated based on the high 
and low value pools included in each assay.  
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Salivary assays have higher variability than serum assays, because their measuring 
levels are one to two orders of magnitude lower in concentration. In the present study 
measurements of 17β-estradiol at the start and end of the menstrual cycles had higher CV’s. 
The sensitivity of the 17β-estradiol assay (the lowest 17β-estradiol concentration 
distinguishable from 0 at a 95% level) was 4 pmol/l.  Average intra-assay variability was 9%, 
and inter-assay variability ranged from 23% for low pools, to 13% for high pools. Therefore, 
we included 17β-estradiol measurements from aligned cycle days -7 to +6 in the linear 
models. All cycles of the participants were aligned based on the identification of the mid-
cycle drop in salivary 17β-estradiol concentration (aligned cycle day 0). The drop provides an 
estimate of the day of ovulation [26]. A drop in 17β-estradiol could not be identified for 14 
women, hence their cycles could not be aligned and they were not included in the statistical 
analysis. Overall salivary 17β-estradiol concentrations were calculated for all 202 women, 
whereas hormonal indices (e.g. follicular, mid-menstrual and luteal phases) were calculated 
only for the women with aligned cycles (n=188).   
 
Mammograms and mammographic density  
Bilateral two-view mammograms were obtained from all women, during the second 
scheduled visit (between cycle days 7 and 12 after onset of bleeding), at the Centre of Breast 
Imaging, University Hospital of North Norway, Tromsø, using a standard protocol [19,27].  
The left craniocaudal mammograms were digitized and imported into a computerized 
mammographic density assessment program (Madena), developed at the University of 
Southern California School of Medicine (Los Angeles, CA, USA) [28,29]. The density 
measurements were conducted by a trained reader (G. Ursin). These were done as follows: 
First a region of interest (ROI) [13] that included the entire breast, but excluded light artifacts 
such as the pectoralis muscle, prominent veins and fibrous strands was outlined. The 
mammogram reader then used a tinting tool to tint pixels considered to represent areas of 
mammographic density. The Madena software estimated the number of tinted pixels within 
the ROI. Absolute mammographic density represents the tinted pixels within the ROI, and 
percent mammographic density is the ratio of absolute mammographic density to the total 
breast area multiplied by 100. The mammograms were read in four batches, with an equal 
number of mammograms in each batch. A duplicate reading of 26 randomly selected 
mammograms from 2 of the batches showed a Pearson’s correlation coefficient of 0.97. The 
reader was blinded to any characteristics of the study population.  
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Statistical analysis 
To study the associations between characteristics of the women and percent and absolute 
mammographic density, we used Students t-test. Linear mixed models for repeated measures 
were used to investigate the association between fasting high or low serum concentrations of 
IGF-1, IGFBP-3 and GH, in combination with salivary 17β-estradiol concentrations 
throughout an entire menstrual cycle, and the study outcomes; percent and absolute 
mammographic density. This was done to take into account a potential combined effect of 
growth hormones and cycling estrogen throughout the menstrual cycle among premenopausal 
women in relation to mammographic density. 
 Based on plausible biological mechanisms, and previous findings suggesting a 
threshold effect between growth factors and breast cancer development [2], we stratified the 
regression analysis by median split of IGF-1 (25 nmol/l) and GH (0.80 mlU/l). Multivariable 
logistic and linear regression models were used to assess the associations between GH, IGF-1, 
estrogens and mammographic density. In the logistic regression models median split of 
percent and absolute mammographic density were used as dependent variables, >28.5% 
[yes/no], > 32.4 cm2 [yes/no] and the GH-IGF-1 axis, and measures of 17β-estradiol (serum, 
salivary; overall, mid-menstrual, follicular, luteal and area under curve) throughout a 
menstrual cycle as independent variables. The 17β-estradiol levels were included as 
categorical variables (median split) and as continuous variables with one standard deviation 
(SD) increase. In the linear regression models, both percent and absolute mammographic 
density were used as dependent variables, and the GH-IGF-1 axis, and measures of 17β-
estradiol throughout a menstrual cycle as independent variables. The 17β-estradiol levels were 
included as continuous variables with one SD increase.  
The variables, including the breast density measures, were approximately normally 
distributed, thus no transformations were needed. Moreover, there were no observations of 
any outliers that could be driving the associations. Based on previously established 
observations, including results from the same study population [19] and suggested biological 
mechanisms, which may influence breast  density, growth factors or levels of estradiol, 
several models were tested, including a variety of potentially confounding variables. We 
tested whether adjustments for potentially confounding factors such as age (continuous in 
years), BMI (continuous in kg/m2), age at menarche (continuous in years), number of children 
(continuous in numbers), previous oral contraceptive use (categorical, yes/no), alcohol intake 
(continuous in units/week), smoking habits (categorical, yes/no), energy intake (continuous in 
kJ/day) and leisure time activity (continuous in metabolic equivalents [METs] hours/week) 
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influenced our estimates. Previous oral contraceptive use, age at menarche, alcohol intake, 
smoking habits, energy intake and leisure time activity were all tested as potential 
confounders, but as these factors did not influence our results they were not included in the 
final model. The adjustment factors in the final model were age, BMI and number of children. 
IGF-1 and IGFBP-3 were adjusted for each other when appropriate. The area under the curve 
(AUC) for estradiol was calculated for each participant with an aligned cycle (days -10 to +9) 
using the trapezium rule [30]. The results were considered statistically significant when two-
sided p <0.05. The analyses were conducted with SPSS version 21.0. 
 
Ethical considerations 
All the participating women signed an informed consent form. The Regional Committee for 
Medical Research Ethics and the Norwegian Data Inspectorate approved the study. 
 
Results 
Selected general characteristics of the study participants are provided in Table 1. Among 
women with a mean age of 30.7 years, a mean salivary 17β-estradiol concentration of 17.9 
pmol/l, a mean percent mammographic density of 29.8% (median 28.5%), and a mean 
absolute mammographic density of 34.7 cm2 (median 32.4 cm2) was observed (Results not 
presented in table). Age, parity and body composition (BMI, waist circumference and total 
tissue fat) were inversely associated with both percent mammographic density (>28.5 %) and 
absolute mammographic density (>32.4 cm2). We observed IGF-1, IGFBP-3 and growth 
hormone independently, and in association with percent and absolute mammographic density, 
and no trends were observed (Table 1).  
We examined women with high and low levels of growth factors (median split of IGF-
1, IGFBP-3 and GH) in combination with mean salivary 17β-estradiol concentrations, 
throughout the mid-menstrual phase in relation to percent mammographic density. When we 
compared women with high IGF-1 (>25 nmol/l) and lower percent mammographic density 
(≤28.5%), with women with high IGF-1 (>25 nmol/l) and higher percent mammographic 
density (>28.5%); we observed a 38.3% difference in overall average 17β-estradiol (p = 
0.023). Similarly, women with either high IGFBP-3 (>100 nmol/l) or high GH (>0.80 mlU/l) 
and lower percent mammographic density (≤28.5%), compared with women with higher 
percent mammographic density (>28.5%), we observed a difference in overall average 17β-
estradiol of 34.1% (p = 0.024) and 34.2% (p = 0.013), respectively. Among women with low 
IGF-1 (≤25 nmol/l), low IGFBP-3 (≤100 nmol/l) or low GH (≤0.80 mlU/l), we observed no 
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difference in mean salivary 17β-estradiol concentrations for those with higher or lower 
percent mammographic density (Figure 1). The IGF-1:IGFBP-3 ratio showed the same pattern 
as described for IGF-1 and IGFBP-3 alone (data not shown).  
When we stratified by median split of IGF-1, IGFBP-3 and GH, and examined the 
mean salivary 17β-estradiol concentrations throughout the mid-menstrual phase in relation to 
absolute mammographic density, (≤ 32.4 cm2, > 32.4 cm2) no differences were observed 
(results not shown in table). 
In stratified analysis of growth factors (median split), the association between 17β-
estradiol (both as a continuous and binary [median split] variable) and percent mammographic 
density was further evaluated in multivariable analysis (adjusted by age, BMI and number of 
children, and IGFBP-3 or IGF-1 when appropriate). In women with high IGF-1 (>25 nmol/l) 
or high GH (>0.80 mlU/l), a one SD increase in overall average salivary 17β–estradiol was 
associated with a 1.81 (95% confidence interval [CI] 1.08-3.03) and 2.08 (95% CI 1.10-3.94) 
times higher odds for having higher percent mammographic density (>28.5%), respectively. 
Similarly, in women with high levels of IGF-1 or GH, overall average 17β–estradiol above 
versus below median (16.8 pmol/l), was associated with a 4.13 (95% CI 1.33-12.83) and 4.17 
(95% CI 1.41-12.28) times higher odds for having higher percent mammographic density 
(>28.5%), respectively. In women with IGFBP-3 (>100 nmol/l), the corresponding odds was 
3.62 (95% CI 1.15-11.38) (results not shown in table). When we subdivided the menstrual 
cycle into mid-menstrual, follicular and luteal phases, we observed adjusted ORs comparable 
to the results listed above for overall salivary 17β-estradiol. In contrast, serum estrogen was 
not associated with percent mammographic density (Tables 2 and 3). The current study did 
not reveal any association between IGF-1, IGFBP-3 and GH in combination with 17β-
estradiol and absolute mammographic density (Results not shown in table). 
Linear regression was also performed with percent and absolute mammographic 
density as continuous variables. There were no associations between high IGF-1, estrogens 
and mammographic density in the linear regression models. However, among women with 
high GH (>0.80 mlU/l), a one SD increase in overall average and follicular phase salivary 
17β–estradiol was positively associated with percent mammographic density. Thus, no 
associations were found when we used absolute mammographic density as the dependent 
variable (Supplementary table 1 and 2). The association between percent mammographic 
density and different categories of 17β-estradiol and IGF-1 (low 17β-estradiol –low IGF-1, 
low 17β-estradiol –high IGF-1, high 17β-estradiol –low IGF-1, and high 17β-estradiol –high 
IGF-1) were also tested. The category with both high 17β-estradiol and high IGF-1 showed an 
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increased OR for having high percent mammographic density; however the other categories 
were not associated with having high percent mammographic density (results not shown in 
table). 
To test for interaction between the 17β-estradiol variables, and IGF-1, IGFBP-3 or 
GH, all variables were first dichotomized and then entered into logistic regression models 
with interaction terms. In addition, we tested for interaction between 17β-estradiol as a 
continuous variable, and growth factors as dichotomized variables. We observed statistically 
significant interactions between the IGF-1 and AUC of salivary 17β-estradiol, and mid-
menstrual salivary 17β-estradiol, and between GH and overall salivary 17β-estradiol (Tables 2 
and 3). 
 
Discussion 
In the present study, we observed that premenopausal women with higher levels of growth 
factors, in combination with daily salivary 17β-estradiol, have higher odds for having higher 
percent mammographic density, independent of age, BMI and number of children. In women 
with high IGF-1 (>25 nmol/l), or high GH (>0.80 mlU/l), there was a positive relationship 
between 17β-estradiol and percent mammographic density, with up to a doubling in odds by 
one SD increase of salivary 17β-estradiol. These findings were further strengthened in women 
with high IGF-1 or high GH, combined with levels above median of daily cycling 17β –
estradiol (>16.8 pmol/l), as these women had a three- to four times higher odds for having 
higher percent mammographic density (>28.5%).  
The present results extend our own [19], and previous reports [31-33], as we observed 
a positive association between growth factors in combination with estrogen and 
mammographic density, not only an association between estrogen alone and mammographic 
density. Interestingly, a crosstalk between IGF-1 and estrogen in breast cancer development 
has been hypothesized [15-18]. Recently, GH action was studied in a panel of estrogen 
receptor-positive breast cancer cell lines, and GH significantly enhanced 17β-estradiol-
stimulated proliferation in these cells. Interestingly, the combination of GH and 17β-estradiol 
overcame inhibition of IGF-I receptor activity to restore proliferation [18]. These observations 
support a potential joint effect of growth factors and estrogen on breast cancer development. 
Our observations are also partly supported by others [33]. Among premenopausal women, 
positive associations were observed both between IGF-1 and between estrogen and percent 
mammographic density. However, estrogen was assessed on six consecutive days in relation 
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to ovulation and one day in the luteal phase in urine, but interestingly when they adjusted for 
BMI, the association was attenuated [33].  
Interestingly, we did not observe any clear association between any of the growth 
factors alone and percent mammographic density, which is consistent with other studies. 
Recently, no association between GH, IGF-1 and percent and absolute mammographic density 
was observed for either premenopausal or postmenopausal women [6], which correspond to 
the results ofothers [34-36]. Furthermore, our observation of an association between IGF-1 
and percent mammographic density, mainly seen among women with higher levels of IGF-1 
suggest a threshold effect. This association is indirectly supported by Hankinson and co-
authors as they observed an increased breast cancer risk among premenopausal women in the 
upper tertile of IGF-1 only [2]. Whether a linear association or a threshold effect exists 
between growth factors and percent mammographic density may be questioned, but our 
findings of no linear association with an interaction between growth factors, in combinations 
with continuous estrogen and percent mammographic density lends support to a threshold 
effect between growth factors and mammographic density. Other findings may also indirectly 
support a threshold effect only among women with high percent mammographic density. In a 
cohort study from the Netherlands, women aged 35 and older with percent mammographic 
density above 25%, had a 2 times increased odds ratio for breast cancer development [37]. 
Moreover, recently percent mammographic density above 25% was associated with later 
increased postmenopausal breast cancer risk [1]. These results partly support a threshold 
effect, and support our cut off of 28.5% for percent mammographic density as an appropriate 
cut off level. 
To note, our observed association between growth factors in combination with 
estrogen and percent mammographic density, were not observed with absolute 
mammographic density. These findings can partly be explained by the fact that absolute 
mammographic density reflect the dense breast tissue, while percent mammographic density 
reflects fibroglandular and fat tissue [38]. Moreover, such an association between growth 
factors and percent mammographic density has been suggested to reflect cumulative exposure 
of hormones and growth factors in breast stroma and epithelium to stimulate cell division 
[39,38].  Thus, estrogen and growth factors may influence not only the dense area, but the 
stroma and the surrounding adipose tissue. Importantly, others have observed that	  fibroglandular and fat tissue may have independent effects on breast cancer development [40].  
Altogether, even if plausible mechanisms have been suggested, and has been 
supported by experimental studies [41], less is known about the association of the GH-IGF 
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signaling pathway, estrogen and mammographic density. Recently, estrogen and IGF-1 have 
been observed to have synergistic effects on the growth of breast cancer cells [41]. Moreover, 
GH regulates the production of IGF-1, and around 99% of circulating IGF-1 is bound to 
IGFBP-3. IGF binds to the tyrosine kinase receptor, which induces an intracellular signalling 
cascade. IGF-1 receptor activation  primarily leads to proliferation and differentiation [42]. 
The GH, IGF-1 and IGFBP-3 levels are age dependent and decrease after puberty. Some 
studies have examined the GH-IGF signaling pathway in association with mammographic 
density, for both premenopausal and postmenopausal women, but the results are indifferent 
[43,44,34]. For postmenopausal women, however, the growth factor levels, estrogen levels 
and mammographic densities are lower than that for premenopausal women. This may explain 
in part, why no associations between these growth factors and mammographic density have 
been observed for postmenopausal women [34,35,43].  Thus, the higher levels of cyclic 
estrogen and serum level of growth factors may be more likely to capture the aetiologically 
relevant exposure period, and may explain in part why the associations are more pronounced 
among premenopausal women [45]. Furthermore, estrogen and mammographic density varies 
throughout the menstrual cycle and this could partly explain why some studies that measure 
estrogen in serum did not show associations with mammographic density [31,46]. Variations 
in the populations may also be explained by the fact that variations in IGF-1 levels have been 
observed in relation to single-nucleotide polymorphisms as well as lifestyle factors (such as 
age, nutrition, hepatic function) [47].   
Recently, both an independent and a combined effect of endogenous sex hormone and 
percent mammographic density were observed on breast cancer risk [14]. Postmenopausal 
women in the highest tertile of estradiol and with the highest percent mammographic density 
(>24.0%) had an increased breast cancer risk [14]. These observations support that, including 
circulating endogenous estrogen, may add additional information about the complexity using 
mammographic density as a biomarker for breast cancer development.  
Thus, our findings of an association between growth factors, estrogen and percent 
mammographic density with a threshold effect are supported by plausible biological 
mechanisms, and suggested as a crosstalk in cells between the signalling pathways for 
estrogens and IGF-1[15,16]. Importantly, GH and IGF-1 signalling, together with estrogens, 
is essential for the development of the mammary gland, particularly the terminal end-buds. It 
has also been found that during lactation, IGF-1 plays an important role in the maintenance of 
the adult mammary gland [48-50]. Furthermore, percent mammographic density refers to the 
structure of the adipose, epithelial and connective tissue in the breast [51]. Thus, the growth 
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factors and estrogens in combination, are key factors in proliferation of breast cells and are 
potential drivers for breast cancer development [41]. 
In the present study, we observed a positive association between IGFBP-3 and percent 
mammographic density, which is in contrast to others [3]. However, the association between 
IGFBP-3 and breast cancer risk may differ according to whether IGFBP-3 is measured as 
intact, fragmented or total [52]. In our study, serum IGF-1 and IGFBP-3 are measured once in 
serum, but have long half-lives and little daily variations. This seems to be adequate for 
measuring the long-term levels of these peptides [53]. However, GH is normally secreted 
episodically with 7-10 peaks per day, but importantly with a more constant fasting morning 
level, as is the case for many other cycling biological markers and the half-life in serum is 
shorter than that for IGF-1. To minimize these variations, GH was assessed in fasting morning 
samples, as is the case for all other growth factors. However, caution should be exerted when 
interpreting the results.  
The current study benefited from several unique features, such as salivary 
measurements of concentrations of unbound 17β-estradiol collected daily across an entire 
menstrual cycle [23,54], following strict procedures [19] and validated methods [26]. Among 
ovulating premenopausal women, the estrogen levels vary considerably throughout the 
menstrual cycle, and by using daily salivary samples, we were able to measure the free 
biologically active form of estrogen, which is considered to be the ideal measure among 
ovulating premenopausal women [23,26].  Thus, we were able to capture the continuous 
estrogen exposure of the women. Moreover, standardized repeated hormone levels in serum 
were also included. 
Furthermore, mammograms were taken during a narrow time frame in the late 
follicular phase (days 7-12), thereby avoiding the bias of variation in mammographic density 
during the menstrual cycle [55].  The validated computer-assisted method has been observed 
to quantify mammographic density, and shown to give a superior prediction of breast cancer 
risk compared with qualitative methods [28]. All mammograms were read by one experienced 
blinded reader, and the assessed mammographic density was negatively associated with age, 
BMI and number of children [56,57]. Thus, we have adjusted for these confounders in the 
multiple analyses. The study population was homogenous with healthy women aged 25-35 
years from the same cultural background. However, the small sample size of the current study 
and small number of earlier reports underlines the need for further studies. 
In conclusion, based on the biological mechanisms suggested and previous reports, the 
present findings are unique in character, supporting that IGF-1, IGFBP-3 and GH, in 
Frydenberg et.al 01.07.2015 
 
14 
 
combination with cycling bioactive estrogen, may be associated with percent mammographic 
density in premenopausal women. This combination of biomarkers may also be important in 
clinical settings. However, our results are based on a relatively small sample size and should 
be interpreted with caution. Hence, there is a need for replication in larger studies. 
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Table 1 Characteristics of the study population by median split of percent and absolute 
mammographic density: The Norwegian Energy Balance and Breast cancer Aspects (EBBA)-
I study (n=202) a 
 
 Percent mammographic 
densitye (%)  
Absolute mammographic 
densitye (cm2) 
 
 
≤28.5 
(n=101)a 
>28.5 
(n=101)a  
≤32.4 
(n=101)a 
>32.4 
(n=101)a  
Characteristics Mean (SD) Mean (SD) p-value Mean (SD) Mean (SD) 
p-
value 
Age (years) 31.54 (2.72) 29.88 (3.18) <0.001 31.48 (2.80) 29.94 (3.14) <0.001 
Education (total years) 16.14 (3.20) 16.01 (2.88) 0.771 15.92 (2.99) 16.23 (3.09) 0.467 
Body compositionb       
  BMI (kg/m2) 26.15 (3.90) 22.66 (2.73) <0.001 25.42 (4.07) 23.39 (3.19) <0.001 
  Waist circumference (cm) 84.43 (9.92) 74.83 (6.93) <0.001 82.45 (10.35) 76.81 (8.35) <0.001 
  Tissue fat, DEXA scan                  
(%)e 37.95 (6.72) 30.54 (6.55) <0.001 36.39 (7.50) 32.10 (7.10) <0.001 
Reproductive factors       
  Parity (no children)  1.35 (1.21) 0.49 (0.84) <0.001 1.25 (1.14) 0.58 (1.02) <0.001 
  Age at menarche (years) 12.87 (1.31) 13.35 (1.40) 0.011 12.91 (1.34) 13.31 (1.39) 0.038 
  Cycle length (days) 27.87 (3.00) 28.67 (3.22) 0.069 27.78 (3.10) 28.76 (3.10) 0.026 
Serum concentrationsc       
  Glucose (mmol/l) 5.15 (0.59) 4.90 (0.51) 0.002 5.10 (0.62) 4.95 (0.49) 0.049 
  Insulin (pmol/l) 90.42 (61.26) 80.96 (57.60) 0.260 91.06 (68.26) 80.32 (48.97) 0.200 
  IGF-1 (nmol/l) 24.66 (6.27) 25.36 (6.41) 0.439 24.23 (6.00) 25.79 (6.59) 0.079 
  IGFBP-3 (nmol/l) 100.51 (15.93) 100.38 (14.17) 0.951 98.63 (15.17) 102.27 (14.75) 0.085 
  Growth hormone (mlU/l) 3.03 (4.90) 4.21 (7.02) 0.175 3.13 (5.19) 4.11 (6.85) 0.260 
Serum hormonesc       
   Estradiol (pmol/l)  149.60 (72.54) 144.60 (48.67) 0.567 153.07 (73.06) 141.10 (47.24) 0.170 
Salivary hormonesd       
  Overall average 17β-estradiol 
(pmol/l)  17.55 (8.78) 18.50 (8.73) 0.441 17.63 (8.42) 18.43 (9.09) 0.515 
Lifestyle factors       
  Energy intake (kJ/day) 7.94 (1.94) 8.27 (1.85) 0.218 7.89 (1.93) 8.32 (1.85) 0.106 
  Previous use of OC (%) 1.16 (0.37) 1.18 (0.39) 0.708 1.18 (0.39) 1.16 (0.37) 0.708 
  Leisure time (MET 
hours/week) 62.49 (121.61) 53.03 (37.64) 0.456 59.99 (121.14) 55.50 (39.55) 0.724 
  Alcohol (units/week) 2.56 (3.10) 3.24 (3.61) 0.154 2.50 (3.13) 3.30 (3.57) 0.091 
  Current smokers (%) 1.76 (0.43) 1.78 (0.42) 0.710 1.77 (0.42) 1.77 (0.42) 0.970 
 
NOTE: All analyses have used Students t-test 
BMI, body mass index; DEXA, dual-energy X-ray; IGF-1, insulin-like growth factor-1; IGFBP-3, insulin-like 
growth factor binding protein-3; OC, oral contraceptives; MET, metabolic equivalents; SD, standard deviations. 
 
aNumbers may vary due to missing information. 
bMeasurements at days 1-5 after onset of menstrual cycle. 
cSerum samples in early follicular phase: days 1-5 after onset of menstrual cycle. 
dDaily saliva samples throughout an entire menstrual cycle. 
eMammograms and total tissue fat (DEXA) were taken days 7-12 (mid-cycle phase). 
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Table 2 Odds ratios (ORs) with 95 % Confidence interval (CI) for higher percent 
mammographic density (>28.5%) by estrogen among premenopausal women, stratified by 
median split of insulin-like growth factor (IGF)-1.  
 
 IGF-1 
 ≤25 nmol/l n=105a >25 nmol/l n=99a Interaction 
Hormones OR 95% CI OR 95% CI p-value 
Serum 17β-estradiol (pmol/l)      
Early follicularb      
  ≤130.0 1.00 (Referent) 1.00 (Referent)  
  >130.0 1.15 (0.43-3.12) 1.57 (0.56-4.43) 0.776 
Estradiol per 1 SD (61.59 pmol/l) 0.84 (0.47-1.52) 1.22 (0.77-1.95) 0.461 
      
Salivary 17β -estradiol (pmol/l)      
Overallc      
  ≤16.8 1.00 (Referent) 1.00 (Referent)  
  >16.8 1.21 (0.42-3.46) 4.13 (1.33-12.83) 0.056 
Estradiol per 1 SD (8.79 pmol/l) 1.52 (0.81-2.82) 1.81 (1.08-3.03) 0.356 
      
Mid-menstrualc      
  ≤16.9 1.00 (Referent) 1.00 (Referent)  
  >16.9 1.10 (0.35-3.44) 4.35 (1.42-13.35) 0.028 
Estradiol per 1 SD (8.98 pmol/l) 1.38 (0.67-2.86) 1.80 (1.09-2.97) 0.183 
      
Folliculare      
  ≤17.5 1.00 (Referent) 1.00 (Referent)  
  >17.5 1.35 (0.44-4.16) 3.84 (1.20-12.26) 0.057 
Estradiol per 1 SD (9.58 pmol/l) 1.39 (0.69-2.80) 1.99 (1.14-3.48) 0.101 
      
Lutealf      
  ≤15.5 1.00 (Referent) 1.00 (Referent)  
  >15.5 1.91 (0.61-6.00) 5.26 (1.67-16.56) 0.071 
Estradiol per 1 SD (9.22 pmol/l)  1.28 (0.64-2.57) 1.62 (1.02-2.58) 0.282 
      
AUCg (pmol/l x cycle)      
  ≤251.25 1.00 (Referent) 1.00 (Referent)  
  >251.25 1.25 (0.40-3.90) 4.35 (1.42-13.35) 0.038 
AUC per 1 SD (133.01 pmol/l x cycle)   1.38 (0.67-2.86) 1.81 (1.10-3.01) 0.176 
 
NOTE: All analyses have used multivariable logistic regression models, and are adjusted for age (continuous), 
body mass index (continuous), number of children (continuous), and IGFBP-3 (continuous). 
AUC, area under curve; CI, confidence interval; IGF-1, insulin-like growth factor-1; IGFBP-3, insulin-like 
growth factor binding protein-3; OR, odds ratio; SD, standard deviation. 
 
aNumbers may vary due to missing information. 
bSerum samples in early follicular phase: days 1-5 after onset of menstrual cycle. 
cDaily saliva samples throughout an entire menstrual cycle. 
dDaily saliva samples in mid-menstrual phase: aligned cycle days -7,+6 
eDaily saliva samples in follicular phase: aligned cycle days -7,-1. 
fDaily saliva samples in luteal phase: aligned cycle days 0,+6 
gAUC estimated from aligned cycle days -10,+9 
P=0.243	  
P=0.155	  
c)	  
e)	  
	  
	  
a)	  
	  
e)	  
c)	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Table 3 Odds ratios (ORs) with 95 % Confidence interval (CI) for higher percent 
mammographic density (>28.5 %) by estrogen among premenopausal women, stratified by 
median split of growth hormone (GH). 
 
 GH  
 ≤0.80 mlU/l n=102a >0.80 mlU/l n=93a Interaction 
Hormones OR 95% CI OR 95% CI p-value 
Serum 17β -estradiol (pmol/l)      
Early follicularb      
  ≤130.0 1.00 (Referent) 1.00 (Referent)  
  >130.0 1.00 (0.35-2.78) 2.27 (0.76-6.73) 0.321 
Estradiol per 1 SD (61.59 pmol/l) 1.08 (0.59-1.98) 1.02 (0.63-1.63) 0.743 
      
Salivary 17β -estradiol (pmol/l)      
Overallc      
  ≤16.8 1.00 (Referent) 1.00 (Referent)  
  >16.8 0.88 (0.30-2.61) 4.17 (1.41-12.28) 0.024 
Estradiol per 1 SD (8.79 pmol/l) 1.57 (0.91-2.69) 2.08 (1.10-3.94) 0.256 
      
Mid-menstruald      
  ≤16.9 1.00 (Referent) 1.00 (Referent)  
  >16.9 1.16 (0.37-3.59) 3.05 (1.02-9.12) 0.170 
 Estradiol per 1 SD (8.98 pmol/l) 1.56 (0.89-2.75) 2.06 (1.06-4.00) 0.328 
      
Folliculare      
  ≤17.5 1.00 (Referent) 1.00 (Referent)  
  >17.5 1.19 (0.38-3.73) 4.09 (1.27-13.12) 0.083 
Estradiol per 1 SD (9.58 pmol/l) 1.40 (0.83-2.37) 2.78 (1.29-6.03) 0.063 
      
Lutealf      
  ≤15.5 1.00 (Referent) 1.00 (Referent)  
  >15.5 2.34 (0.71-7.77) 3.70 (1.25-10.96) 0.361 
Estradiol per 1 SD (9.22 pmol/l) 1.69 (0.94-3.03) 1.58 (0.88-2.84) 0.949 
      
AUCg (pmol/l x cycle)      
  ≤251.25 1.00 (Referent) 1.00 (Referent)  
  >251.25 1.33 (0.43-4.12) 3.05 (1.02-9.12) 0.586 
AUC per 1 SD (133.01 pmol/l x cycle) 1.60 (0.91-2.83) 2.06 (1.05-4.04) 0.348 
  
NOTE: All analyses have used multivariable logistic regression models, and are adjusted for age (continuous), 
body mass index (continuous), and number of children (continuous). 
AUC, area under curve; CI, confidence interval; GH, growth hormone; OR, odds ratio; SD, standard deviation. 
 
aNumbers may vary due to missing information. 
bSerum samples in early follicular phase: days 1-5 after onset of menstrual cycle. 
cDaily saliva samples throughout an entire menstrual cycle. 
dDaily saliva samples in mid-menstrual phase: aligned cycle days -7,+6 
eDaily saliva samples in follicular phase: aligned cycle days -7,-1. 
fDaily saliva samples in luteal phase: aligned cycle days 0,+6 
gAUC estimated from aligned cycle days -10,+9	  
